Search research articles
Contact Us
Filters
Showing results (191-200 of 231) with videos related to
Page
of 24
Sort By:
Blood
|
April 28, 2016
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Bruno Paiva, Maria-Teresa Cedena, Noemi Puig, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 10, 2022
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
Luis-Esteban Tamariz-Amador, Paula Rodríguez-Otero, Ana Jiménez-Ubieto, et al.
Blood Cancer Discovery
|
March 11, 2026
Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancers
Carmen González, Juan-Jose Garces, Hector Gracia, et al.
Blood
|
May 22, 2025
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment
Marta Lasa, Carmen Gonzalez, Laura Notarfranchi, et al.
Blood Cancer Discovery
|
March 5, 2024
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Irene M Ghobrial, Nicole Gormley, Shaji K Kumar, et al.
American Journal of Hematology
|
March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Holger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
Leukemia
|
August 12, 2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Luciano J Costa, Benjamin A Derman, Susan Bal, et al.
American Journal of Hematology
|
June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Shambavi Richard, Ajai Chari, Sosana Delimpasi, et al.
Blood Advances
|
November 27, 2024
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma
Inés Zugasti, Marta Tormo-Ratera, Aina Oliver-Caldés, et al.
The New England Journal of Medicine
|
December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
Meletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
Page
of 24
Search research articles
Search
Showing results (191-200 of 231) with videos related to
Sort By:
Page
of 24
Blood
|
April 28, 2016
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Bruno Paiva, Maria-Teresa Cedena, Noemi Puig, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 10, 2022
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
Luis-Esteban Tamariz-Amador, Paula Rodríguez-Otero, Ana Jiménez-Ubieto, et al.
Blood Cancer Discovery
|
March 11, 2026
Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancers
Carmen González, Juan-Jose Garces, Hector Gracia, et al.
Blood
|
May 22, 2025
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment
Marta Lasa, Carmen Gonzalez, Laura Notarfranchi, et al.
Blood Cancer Discovery
|
March 5, 2024
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Irene M Ghobrial, Nicole Gormley, Shaji K Kumar, et al.
American Journal of Hematology
|
March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Holger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
Leukemia
|
August 12, 2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Luciano J Costa, Benjamin A Derman, Susan Bal, et al.
American Journal of Hematology
|
June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Shambavi Richard, Ajai Chari, Sosana Delimpasi, et al.
Blood Advances
|
November 27, 2024
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma
Inés Zugasti, Marta Tormo-Ratera, Aina Oliver-Caldés, et al.
The New England Journal of Medicine
|
December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
Meletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
Page
of 24